0 Commentaires
0 Parts
26 Vue
0 Aperçu
Rechercher
Découvrez de nouvelles personnes, créer de nouvelles connexions et faire de nouveaux amis
-
Connectez-vous pour aimer, partager et commenter!
-
MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval Creating a New Rare-Disease Revenue Stream?MEK inhibitors targeting neurofibromatosis type 1-associated plexiform neurofibromas — the oral allosteric MEK1/2 inhibitors selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringWorks Therapeutics) approved for pediatric and adult NF1 patients with symptomatic, inoperable tumors — represent the fastest-growing indication segment in the MEK inhibitor market, with the...0 Commentaires 0 Parts 190 Vue 0 Aperçu